Alaunos Therapeutics (TCRT) EBITDA Margin (2011 - 2025)
Alaunos Therapeutics' (TCRT) quarterly EBITDA Margin came in at 30233.33% in Q4 2025, down 1135833.0% YoY from N/an in Q4 2024, and up 44.63% on a QoQ basis from 54600.0% in Q1 2025.
Alaunos Therapeutics (TCRT) EBITDA Margin (2011 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 13 years of EBITDA Margin data on file, last reported at 30233.33% in Q4 2025.
- Quarterly EBITDA Margin fell 1135833.0% year-over-year to 30233.33% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 138166.67% (down 9653667.0% YoY) and the FY2025 annual result came in at 84500.0%, down 3638000.0% from the prior year.
- EBITDA Margin advanced to 30233.33% in Q4 2025, from 54600.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 77463.64% in Q4 2022 to a low of 794900.0% in Q4 2023.
- A 5-year average of 162043.69% and a median of 30233.33% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 87236364 bps — and 2024, when it soared 77602500 bps.
- Tracing TCRT's EBITDA Margin over 5 years: stood at 552550.0% in 2021, then soared by 114 bps to 77463.64% in 2022, then plunged by 1126 bps to 794900.0% in 2023, then soared by 98 bps to 18875.0% in 2024, then sank by 60 bps to 30233.33% in 2025.
- The last three EBITDA Margin figures came in at 30233.33% (Q4 2025), 54600.0% (Q1 2025), and 18875.0% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30,233.33% |
| Mar 31, 2025 | -54,600.00% |
| Dec 31, 2024 | -18,875.00% |
| Jun 30, 2024 | -29,150.00% |
| Mar 31, 2024 | -174,200.00% |
| Dec 31, 2023 | -794,900.00% |
| Jun 30, 2023 | -199,550.00% |
| Dec 31, 2022 | 77,463.64% |
| Sep 30, 2022 | -283.89% |
| Dec 31, 2021 | -552,550.00% |
| Sep 30, 2021 | -5,602.01% |
| Mar 31, 2018 | -11,093.15% |
| Dec 31, 2017 | -841.33% |
| Sep 30, 2017 | -818.40% |
| Jun 30, 2017 | -814.90% |
| Mar 31, 2017 | -874.45% |
| Dec 31, 2016 | -695.74% |
| Sep 30, 2016 | -682.98% |
| Jun 30, 2016 | -7,733.77% |
| Mar 31, 2016 | -611.48% |